论文部分内容阅读
目的:观察用较大剂量尿激酶一次性冲击治疗急性脑梗塞的疗效及安全性。方法:21例尿激酶治疗组与同期23例蝮蛇抗栓酶对照组,在治疗第1天和第10天进行疗效比较,观察不良反应。结果:治疗第一天治疗组治愈显效率为57.1％,对照组为4.3％(P<0.01)差异极显著。治疗第10天治疗组总有效率为85.7％。对照组为60.9％。结论:较大剂量(1.8万~μ/kg)尿激酶一次性冲击治疗急性脑梗塞疗效较为理想,较蝮蛇抗栓酶为佳。开始溶栓时间越早越好,发病6～8小时溶栓仍有一定疗效,其安全较好。
Objective: To observe the curative effect and safety of treating acute cerebral infarction with larger dose of urokinase. Methods: 21 cases of urokinase treatment group and 23 cases of viper antithrombotic control group at the same time, the first day and the 10th day of treatment were compared, the adverse reactions were observed. Results: On the first day of treatment, the effective rate of cure was 57.1% in the treatment group and 4.3% in the control group (P <0.01). On the 10th day of treatment, the total effective rate in the treatment group was 85.7%. The control group was 60.9%. Conclusion: The larger dose (1.8 million ~ μ / kg) of urokinase one-time impact treatment of acute cerebral infarction is more ideal than the Viper antithrombotic better. Start the thrombolytic time the sooner the better, the incidence of 6 to 8 hours thrombolysis still have some effect, its safety is better.